Summary
Radio- and chemotherapy for the treatment of malignancies are often associated with significant toxicity. One approach to reduce the toxicity is the concomitant treatment with chemoprotective agents. This article reviews two sulfhydryl compounds, namely the agent WR-2721 (amifostine), a compound recently registered for use in human in many countries, and the natural occurring compound glutathione (GSH). GSH is not registered as a chemoprotective agent. WR-2721 is an aminothiol prodrug and has to be converted to the active compound WR-1065 by membrane-bound alkaline phosphatase. WR-1065 and GSH both act as naturally occurring thiols. No protective effect on the tumour has been found when these compounds are administered intravenously. There is even in vitro evidence for an increased anti-tumour effect with mafosfamide after pretreatment with WR-2721, and in vivo after treatment with carboplatin and paclitaxel. Randomized clinical studies have shown that WR-2721 and GSH decrease cisplatin-induced nephrotoxicity and that WR-2721 reduces radiation radiotherapy-induced toxicity. Side-effects associated with WR-2721 are nausea, vomiting and hypotension, GSH has no side-effects. An exact role of WR-2721 and GSH as chemoprotectors is not yet completely clear. Future studies should examine the protective effect of these drugs on mucositis, cardiac toxicity, neuro- and ototoxicity, the development of secondary neoplasms and their effect on quality of life.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aebi, S., Assereto, R. & Lauterburg, B. H. (1991). High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest 21: 103–110.
Alberts, D. S. & Noel, J. K. (1995). Cisplatin associated neurotoxicity, can it be prevented? Anticancer Drugs 6: 369–383.
Alberts, D. S., Liu, P. Y., Hanigan, E. V., O’Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., Dubeshter, B., Adelson, M. D. & Hoskins, W. J. (1996). Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1956.
Ben-Josef, E., Mesina, J., Shaw, L. M., Bonner, H. S., Shamsa, F. & Porter, A. T. (1995). Topical application of WR-2721 achieves high concentrations in the rectal wall. Radiation Res 143: 107–110.
Betticher, D. C., Anderson, H., Ranson, M., Meeley, K., Oster, W. & Thatcher, N. (1995). Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer. A randomized phase II study. Br J Cancer 72: 1551–1555.
Bogliun, G., Marzorati, L., Marzola, M., Miceli, M. D., Cantu, M. G. & Cavaletti, G. (1996). Neurotoxicity of cisplatin +/− reduced glutathione in the first-line treatment of advanced ovarian cancer. Int J Gynaecol Cancer 6: 415–419.
Brizel, D., Sauer, M., Wannenmacher, M., Henke, M., Eschwege, F. & Wasserman, T. (1998). Randomized phase III trial of radiation +/− amifostine in patients with head and neck cancer. Proc Am Soc Clin Oncol 17: Abstract # 1487
Budd, G. T. (1996). Amifostine and chemotherapy-related thrombocytopenia. Semin Oncol 23: 49–52.
Budd, G. T., Bukowski, R. M., Adelstein, D., Pelley, R., Olencki, T., Petrus, J. V., McLain, D., Conlon, J., Kurman, M., Capizzi, R. L. & Ganapathi, R. (1996). Mature results of a randomized trial of carboplatin and amifostine vs carboplatin alone in patients with advanced malignancies. Proc Am Soc Clin Oncol 15: (abstract) 1720
Buntzel, J., Kuttner, K., Frohlich, D. & Glatzel, M. (1998). Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 9: 505–509.
Calabro-Jones, P. M., Fahey, R. C., Smoluk, G. D. & Ward, J. F. (1985). Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79–171 cells incubated in medium containing WR-2721. Int J Radiat Biol 47: 23–27.
Calabro-Jones, P. M., Aguilera, J. A., Ward, J. F., Smoluk, G. D. & Fahey, R. C. (1988). Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 48: 3634–3640.
Capizzi, R. L. & Oster, W. (1995). Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experience. Eur J Cancer 31A: 8–13.
Delaney, J. P., Bonsack, M. E. & Felemovicius, I. (1994). Radioprotection of the rat small intestine with topical WR-2721. Cancer 74: 2379–2384.
De Wit, R. (1995). Four cycles of BEP versus an altering regime of PVB and BEP in patients with poor prognosis metastatic testicular non-seminoma. A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71: 1311–1314.
DiPaola, R. S., Rodriguez, R., Goodin, S., Recio, A., Orlick, M., Mollman, J., Bird, S., Belsh, J. M., Schein, P. S., Aisner, J. & Schuchter, L. M. (1998). Amifostine and dose-intense paclitaxel in patients with advanced malignancies. Cancer Therapeutics 1: 11–17.
Di Re, F., Bohm, S., Oriana, S., Spatti, G. B. & Zunino, F. (1990). Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother Pharmacol 25: 355–360.
Di Re, F., Bohm, S., Oriana, S., Spatti, G. B., Pirovano, C., Tedeschi, M. & Zunino, F. (1993). High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol 4: 55–61.
Dorr, R. T. (1996). Cytoprotective agents for anthracyclines. Semin Oncol 23: 23–24.
Douay, L., Hu, C., Giarratana, M-C, Bouchet, S., Conlon, J., Capizzi, R. L. & Gorin, N-C (1995). Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 86: 2849–2855.
Dunn, T. A., Schmoll, H. J., Grunwald, V., Bokemeyer, C. & Casper, J. (1996). Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. Anticancer Drugs 7: 795–799.
Ercan, M. T., Aras, T., Aktas, A., Kaya, S. & Bekdik, C. F. (1994). Accumulation of 99mTc-glutathione in head and neck tumors. Nuklearmedizin 33: 224–228.
Glick, J. H., Glover, D. J. & Weiler, C. (1984). Phase I controlled trials of WR-2721 and cyclophosphamide. Int J Oncol Biol Phys 10: 1777–1780.
Glover, D., Glick, J. H., Weiler, C., Fox, K., Turrisi, A. & Klingerman, M. M. (1986). Phase I/II trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 12: 1509–1512.
Grdina, D. J., Kataoka, Y. & Basic, I. (1992). The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation. Carcinogenesis 13: 811–813.
Grdina, D. J., Shigematsu, N., Dale, P., Nemton, G. L., Aguilera, J. A. & Fahey, R. C. (1995). Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 16: 767–774.
Gyenes, G., Fornander, T., Carlens, P. & Skovsgaard, T. (1996). Morbidity of ischemic heart disease in early breast cancer 15–20 years after adjuvant radiotherapy. Int J Rad Oncol Biol Phys 28: 1235–1241.
Hamers, F. P. T., Brakkee, J. H., Cavalletti, E., Tedeschi, M., Marmonti, L., Pezzoni, G., Neijt, J. P. & Gispen, W. H. (1993). Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 53: 544–549.
Hill, C. K., Nagy, B. & Persaino, C. (1986). WR-2721 is anti-neoplastic and anti-mutagenic when given during 60Co γ-ray irradiation. Carcinogenesis 7: 665–668.
Kaltenbach, J. A., Church, M. W., Blakley, B. W., McCaslin, D. L. & Burgio, D. L. (1997). Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg 117: 493–500.
Kataoka, Y., Basic, I. & Perrin, J. (1992). Antimutagenic effects of radioprotector WR-2721 against fission spectrum neutrons and 60Co γ-rays in mice. Int J Radiat Biol 61: 387–392.
Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D. & Glick, J. (1996). Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized controlled trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101–2112.
Korst, A. E. C., Eeltink, C. M., Vermorken, J. B. & Van de Vijgh, W. J. F. (1997). Pharmacokinetics of amifostine and its metabolites in patients. Eur J Cancer 33: 1425–1429.
Leone, R., Fracasso, M. E., Soresi, E., Cimino, G., Tedeschi, M., Castoldi, D., Monzani, V., Colombi, L., Usari, T. & Bernareggi, A. (1992). Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin. Cancer Chemother Pharmacol 29: 385–390.
Lipschulz, S. E., Colan, S. D., Gelber, R. D., Peres-Atayde, A. R., Sallan & Sanders, S. P. (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood. N Engl J Med 324: 808–815.
List, A. F., Brasfield, F., Heaton, R., Glinsmann-Gibson, B., Crook, L., Taetle, R. & Capizzi, R. (1997). Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90: 3364–3369.
Liu, T. F., Liu, Y., He, S., Zhang, Z. & Kligerman, M. M. (1992). The use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 69: 2820–2825.
Liu, S. C., Murley, J. S., Woloschak, G. & Grdina, D. J. (1997). Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis 18: 2457–2459.
Locatelli, M. C., D’Antona, A., Labianca, R., Vinci, M., Tedeschi, M., Carcione, R., Corbo, A., Venturino, P. & Luporini, G. (1993). A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity. Tumori 79: 37–39.
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L. & Davidson, M. (1996). Cyclophosphamide and cisplatin compared with taxol and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 33: 1–6.
Mangold, D. J., Miller, M. A., Huelle, B. K., Sanchez-Barona, D. O., Swynnerton, N. F., Flechenstein, L. & Ludden, T. M. (1989). Disposition of the radioprotector ethiofos in the rhesus monkey. Influence of route of administration. Drug Metab Dispos 17: 304–310.
Meister, A. (1983). Selective modification of glutathione metabolism. Science 220: 472–477.
Milas, L., Hunter, N., Stephens, L. C. & Peters, L. J. (1984). Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid). Cancer Res 44: 5567–5569.
Millar, J. L., McElwain, T. J., Clutterbuck, R. D. & Wist, E. A. (1982). The modification of melphalan toxicity in tumour bearing mice by WR-2721. Am J Clin Oncol 5: 321–328.
Mollman, J. E., Glover, D. J., Hogan, W. M. & Furman, R. E. (1988). Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61: 2192–2195.
Montana, G. S., Anscher, M. S., Mansbach, IICM, Daly, N., Delannes, M., Clarke-Pearson, D. & Gaydica, F. (1992). Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. Cancer 69: 2826–2830.
Mori, T., Nikaido, O. & Sugahara, T. (1984). Dephosphorylation of WR-2721 with mouse tissue homogenates. Int J Radiat Oncol Biol Phys 10: 1529–1531.
Murley, J. S. & Grdina, D. J. (1995). The effects of cycloheximide and WR-1065 on radiation-induced repair processes: a mechanism for chemoprevention. Carcinogenesis 16: 2699–2705.
Murley, J. S., Constantinou, A., Kamath, N. S. & Grdina, D. J. (1997). WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Profil 30: 283–294.
Nagy, B. & Grdina, D. J. (1986). Protective effects of WR-2721 against bleomycin and nitrogen mustard-induced mutagenicity in V76 cells. Int J Radiat Oncol Biol Phys 12: 1475–1478.
Nagy, B., Dale, P. J. & Grdina, D. J. (1986). Protection against cis diamminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by WR-2721. Cancer Res 46: 1132–1135.
Nooijen, P. T., Westphal, J. R., Eggermont, A. M., Schalkwijk, C., Max, R., De Waal, R. M. & Ruiter, D. J. (1998). Endothelial P-selectin expression is reduced an advanced primary melanoma and melanoma metastasis. Am J Pathol 152: 679–682.
Parnis, F. X., Coleman, R. E., Harper, P. G., Pickering, D., Topham, C., Whittington, J. R. & Tedeschi, M. (1995). A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer. Eur J Cancer 31A: 1721
Planting, A. S. T., Vermorken, J. B., Catimel, G., De Mulder, P. H. M., De Graeff, A., Oster, W. & Hoppener, F. (1996). Randomized phase II study of cisplatin with and without amifostine in patients with advanced head and neck cancer. Proc Am Soc Clin Oncol 15: abstract # 887
Poplin, E. A., LoRusso, P. & Lokich, J. J. (1994). Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 33: 415–419.
Romero, F. J., Segura-Aguilar, J., Monsalre, E., Hermenegildo, C., Nies, E., Puertas, F. J. & Roma, J. (1990). Antioxidant and glutathione-related enzymatic activities in rat sciatic nerve. Neurotoxicol Teratol 12: 603–605.
Rubin, J. S., Wadler, S., Beitler, J. J., Haynes, H., Rozenblit, A., McGill, F., Goldberg, G. & Runowicz, C. (1995). Audiological findings in a phase I protocol investigating the effect of WR-2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. J Laryngol Otol 109: 744–747.
Sajjan, A. R., Hinchigeri, S. B. & Datta, K. S. (1991). Multiple forms of γ-glutamyl transpeptidase in human submandibular gland. Clin Chim Acta 197: 133–139.
Schiller, J. H., Storer, B. & Berlin, J. (1996). Amifostine, cisplatin and vinblastine in metastatic non-small-cell lung cancer; a report of high response rates and prolonged survival. J Clin Oncol 14: 1913–1921.
Schwindt, E. A., Collet, A. M., Mendez, A. E., Cabrini, R. L. & Itoiz, M. E. (1992). The first normal oral epithelium which γ-glutamyl transpeptidase activity has been detected. Histochem J 24: 964–968.
Shapiro, C. L. & Henderson, I. C. (1994). Late cardiac effects of adjuvant therapy: too soon to tell?. Ann Oncol 5: 196–198.
Shaw, L. M., Turrisi, A. T. & Glover, D. J. (1986). Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12: 1501–1504.
Shaw, L. M., Bonner, H., Nakashima, H. & Lieberman, R. (1994). Evidence for saturable metabolism. Proc Am Soc Clin Oncol 13: abstract # 144
Shpall, E. J., Stemmer, S. M., Hami, L., Franklin, W. A., Shaw, L., Bonner, H. S., Bearman, S. I., Peters, W. P., Bast, R. C., McCulloch, W., Capizzi, R., Mitchell, E., Schein, P. S. & Jones, R. B. (1994). Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxy-cyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83: 3132–3137.
Smoluk, G. D., Fahey, R. C., Calabro-Jones, P. M., Aguilera, J. A. & Ward, J. F. (1988). Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res 48: 3641–3647.
Smyth, I., Bowman, A., Perren, T., Wilkinson, P., Prescott, R., Quinn, K. J. & Tedeschi, M. (1997). Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind randomised trial. Ann Oncol 8: 569–573.
Steinherz, L. J. & Yahalom, J. (1993). Cardiac complications of cancer therapy. In Cancer Principles & Practice of Oncology, De Vita VT, Hellman S and Rosenberg SA (eds), pp. 2370–2385. Lippincott: Philadelphia
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., Speyer, J., Mittelman, A., Reddy, S., Pendergrass, K., Velez-Garcia, E., Ewer, M. S., Bianchine, J. R. & Gams, R. A. (1997). Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15: 1318–1332.
Taylor, C. W., Wang, L. M., List, A. F., Fernandes, D., Paine-Murrieta, G. D., Johnson, C. S. & Capizzi, R. L. (1997). Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer 33: 1693–1698.
Thompson, D. C., Wyrick, S. D., Holbrook, D. J. & Chaney, S. G. (1995). HPLC and 31P NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). Biochem Pharmacol 50: 1413–1419.
Treskes, M., Holwerda, U., Klein, I., Pinedo, H. M. & Van der Vijgh, W. J. F. (1991). The chemical reactivity of the modulating agent WR-2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol 42: 2125–2130.
Treskes, M., Boven, E., Van de Loosdrecht, A. A. & Wijffels, JFAM (1994). Effects of the modulating agent WR-2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 30A: 183–187.
Utley, J. F., Marlowe, C. & Waddell, W. J. (1976). Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse. Radiat Res 68: 284–291.
Valeriote, F. & Tolen, S. (1982). Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 42: 4330–4331.
Van der Vijgh, W. J. & Korst, A. E. (1996). Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. Eur J Cancer 32A(4): S26–S30
Washburn, L. C., Rafter, J. J., Hayes, R. L. & Yuhas, J. M. (1976). Prediction of the effective radioprotective dose of WR-2721 in humans through an interspecies tissue distribution study. Radiat Res 66: 100–105.
Wasserman, T. H., Philips, T. L., Ross, G. & Kane, L. J. (1981). Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 4: 3–6.
Weiss, J. F. (1997). Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ Health Perspect 105S: (suppl 6) 1473–1478.
Wooley, P. V., Ayoob, M. J. & Smith, F. P. (1983). Clinical trial of the effect of S-2(3- aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide. J Clin Oncol 5: 198–203.
Yuhas, J. M. (1980). Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 40: 1519–1524.
Zunino, F., Prates, G., Micheloni, A., Cavalleti, E., Sala, F. & Tofanetti, O. (1989). Protective effect of reduced glutathione against cisplatin induced renal and systemic toxicity and its influence on the therapeutic activity of the anti-tumour drug. Chem Biol Interact 70: 89–101.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hospers, G., Eisenhauer, E. & Vries, E. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer 80, 629–638 (1999). https://doi.org/10.1038/sj.bjc.6690404
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690404
Keywords
This article is cited by
-
Pterisolic Acid B is a Nrf2 Activator by Targeting C171 within Keap1-BTB Domain
Scientific Reports (2016)
-
The in vitro protective effect of salicylic acid against paclitaxel and cisplatin-induced neurotoxicity
Cytotechnology (2016)
-
Pyrrolidine dithiocarbamate (PDTC) blocks apoptosis and promotes ionizing radiation-induced necrosis of freshly-isolated normal mouse spleen cells
Apoptosis (2010)
-
Amifostine prior to lethal irradiation prevents allogeneic bone marrow engraftment in mice
Bone Marrow Transplantation (2008)
-
In vitro anti— irradiation effects of a polypeptide from Chlamys farreri
Chinese Journal of Clinical Oncology (2005)